Your browser doesn't support javascript.
Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic.
Cerbu, Bianca; Pantea, Stelian; Bratosin, Felix; Vidican, Iulia; Turaiche, Mirela; Frent, Stefan; Borsi, Ema; Marincu, Iosif.
  • Cerbu B; Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Pantea S; Surgical Clinic 2 Department, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Bratosin F; Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Vidican I; Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Turaiche M; Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Frent S; Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Borsi E; Department of Internal Medicine-Hematology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Marincu I; Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Medicina (Kaunas) ; 57(6)2021 Jun 10.
Article in English | MEDLINE | ID: covidwho-1264492
ABSTRACT
Background and

Objectives:

The COVID-19 pandemic is an ongoing public health emergency. Patients with chronic diseases are at greater risk for complications and poor outcomes. The objective of this study was to investigate the liver function abnormalities and clinical outcomes in patients with COVID-19 and chronic hepatitis C. Materials and

Methods:

This retrospective, single-center study was conducted on a cohort of 126 patients with a history of hepatitis C, confirmed with COVID-19 between 01 April 2020 and 30 December 2020. Several clinical outcomes were compared between patients with active and non-active HCV infection, and the risks of liver impairment and all-cause mortality in active HCV patients were analyzed using a multivariate logistic regression model.

Results:

Among 1057 patients under follow-up for chronic HCV infection, 126 (11.9%) were confirmed with COVID-19; of these, 95 (75.4%) were under treatment or achieved SVR, while in the other 31 (24.6%), we found active HCV replication. There was a significantly higher proportion of severe COVID-19 cases in the active HCV group as compared to the non-active HCV group (32.2 vs. 7.3%, p < 0.001). Multivariate analysis showed that age, sex, alanine aminotransferase, C-reactive protein, procalcitonin, and HCV viral load were significant independent risk factors for liver impairment and all-cause mortality. The length of stay in hospital and intensive care unit for COVID-19 was significantly higher in patients with active HCV infection (p-value < 0.001), and a higher proportion of these patients required mechanical ventilation.

Conclusions:

Active HCV infection is an independent risk factor for all-cause mortality in COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hepatitis C, Chronic / COVID-19 Type of study: Observational study / Prognostic study / Risk factors Limits: Humans Language: English Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Medicina57060597

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hepatitis C, Chronic / COVID-19 Type of study: Observational study / Prognostic study / Risk factors Limits: Humans Language: English Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Medicina57060597